Working to deliver
better outcomes with fewer risks
Cell therapies have made significant advancements in recent years; however, their broad use is still limited by the risks these treatments can pose. At Orca Bio, we don't accept these limitations—we believe by making cell therapies both safer and more effective, we could push past current boundaries and redefine the future of treatment.
We are currently studying our investigational high-precision cell therapies in several of the most prevalent blood cancers. We are encouraged by our progress and the hope it represents for patients living with serious blood cancers, but these programs are only the beginning.
Our long-term plan is to not only treat serious blood cancers, but develop cell therapies for even more patients who have other blood disorders, solid tumor malignancies, and chronic conditions who could benefit from our platform.
AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; IND = Investigational New Drug Application; MDS = myelodysplastic syndrome; MF = myelofibrosis; MPAL = mixed phenotype acute leukemia.
Learn more about Orca-T and Orca-Q below.
Orca-T is designed to replace a patient's cancerous blood and immune system with a healthy one, while dramatically lowering their risk of developing GvHD and other potentially life-threatening transplant-related side effects.
In our Phase Ib/II study, when measured against a concurrent, nonrandomized single-center comparator for allogeneic transplant patients, Orca-T demonstrated preliminary evidence of:
- Significantly higher GvHD-free, relapse-free survival rates after 1 year
- Lower rates of chronic GvHD
To verify these preliminary results in a larger patient population, we plan to initiate a randomized, Phase III pivotal trial of Orca-T.
While our lead investigational therapy candidate, Orca-T, requires a fully matched donor for the allogeneic stem cell transplant, we are also developing Orca-Q, a next-generation investigational cell therapy candidate. Orca-Q is designed to deliver therapeutic benefits without the need for a fully matched donor.
Our vision is that Orca-Q could unlock the therapeutic benefits of a transplant for most patients living with blood cancers who can't find a fully matched donor.
This therapy is currently being investigated in an ongoing Phase I trial.